Oncology & Cancer
Pinpointing how cancer cells turn aggressive
It's often cancer's spread, not the original tumor, that poses the disease's most deadly risk.
Jun 10, 2021
0
20
Cancer Cell
Oncology & Cancer
Research leads to better understanding of the immune system in kidney cancer
In the last two decades, immunotherapy has emerged as a leading treatment for advanced renal carcinoma cancer (more commonly known as kidney cancer). This therapy is now part of the standard of care, but it doesn't work for ...
Mar 11, 2021
0
59
Oncology & Cancer
Collagen plays protective role during pancreatic cancer development
Contrary to long-held beliefs, Type I collagen produced by cancer-associated fibroblasts does not promote cancer development but instead plays a protective role in controlling pancreatic cancer progression, reports a new ...
Mar 4, 2021
0
37
Oncology & Cancer
Aggressive brain tumor mapped in genetic, molecular detail
Glioblastoma is among the most aggressive and devastating of cancers. While rare compared with other cancers, it's the most common type of brain cancer. Even with intensive therapy, relatively few patients survive longer ...
Feb 11, 2021
0
89
Oncology & Cancer
How a little-known glycoprotein blocks a cancer cell's immune response
It was an unexpected discovery that started with an analysis of more than 1,000 genes. The question: why game-changing cancer immunotherapy treatments work for only a fraction of patients.
Jan 28, 2021
0
129
Oncology & Cancer
Errant DNA boosts immunotherapy effectiveness
DNA that ends up where it doesn't belong in cancer cells can unleash an immune response that makes tumors more susceptible to immunotherapy, the results of two UT Southwestern studies indicate. The findings, published online ...
Dec 17, 2020
0
44
Oncology & Cancer
Study of 'exceptional responders' yields clues to cancer and potential treatments
In a comprehensive analysis of patients with cancer who had exceptional responses to therapy, researchers have identified molecular changes in the patients' tumors that may explain some of the exceptional responses. The results ...
Nov 19, 2020
0
28
Oncology & Cancer
Large-scale cancer proteomics study profiles protein changes in response to drug treatments
Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at The University of Texas MD Anderson Cancer Center have generated a valuable resource to aid in predicting ...
Nov 5, 2020
0
20
Oncology & Cancer
Study shows how interferon-gamma guides response to cancer immunotherapy
A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds light on how interferon-gamma (IFN-y), an immune response-stimulating signaling molecule that helps activate immune cells, guides the treatment ...
Sep 10, 2020
0
98
Oncology & Cancer
Combination immunotherapy benefits subset of patients with advanced prostate cancer
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset ...
Sep 10, 2020
0
62
